Skip to main content
Erschienen in:

09.05.2023 | Original Article

Nanoparticles Enhance Solubility and Neuroprotective Effects of Resveratrol in Demyelinating Disease

verfasst von: Ehtesham Shamsher, Reas S. Khan, Benjamin M. Davis, Kimberly Dine, Vy Luong, Satyanarayana Somavarapu, M. Francesca Cordeiro, Kenneth S. Shindler

Erschienen in: Neurotherapeutics | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Resveratrol is a natural polyphenol which may be useful for treating neurodegenerative diseases such as multiple sclerosis (MS). To date, current immunomodulatory treatments for MS aim to reduce inflammation with limited effects on the neurodegenerative component of this disease. The purpose of the current study is to develop a novel nanoparticle formulation of resveratrol to increase its solubility, and to assess its ability to prevent optic nerve and spinal cord degeneration in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Resveratrol nanoparticles (RNs) were made using a thin rehydration technique. EAE mice received a daily oral administration of vehicle, RNs or unconjugated resveratrol for one month. They were assessed daily for clinical signs of paralysis and weekly for their visual acuity with optokinetic responses (OKR). After one month, their spinal cords and optic nerves were stained for inflammation and demyelination and retinal ganglion cells immunostained for Brn3a. RNs were stable for three months. The administration of RNs did not have any effect on clinical manifestation of EAE and did not preserve OKR scores but reduced the intensity of the disease. It did not reduce inflammation and demyelination in the spinal cord and the optic nerve. However, RNs were able to decrease RGC loss compared to the vehicle. Results demonstrate that resveratrol is neuroprotective by reducing RGC loss. Interestingly, neuroprotective effects and decreased disease severity occurred without reduction of inflammation or demyelination, suggesting this therapy may fill an unmet need to limit the neurodegenerative component of MS.
Literatur
1.
Zurück zum Zitat McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325:765–79.CrossRefPubMed McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325:765–79.CrossRefPubMed
2.
Zurück zum Zitat Fonseca-Kelly Z, Nassrallah M, Uribe J, Khan RS, Dine K, Dutt M, et al. Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol. 2012;3:84.CrossRefPubMedPubMedCentral Fonseca-Kelly Z, Nassrallah M, Uribe J, Khan RS, Dine K, Dutt M, et al. Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol. 2012;3:84.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPI Precis Oncol. 2017;11:1–9. Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPI Precis Oncol. 2017;11:1–9.
5.
Zurück zum Zitat Drygalski K, Fereniec E, Koryciński K, Chomentowski A, Kiełczewska A, Odrzygóźdź C, et al. Resveratrol and Alzheimer’s disease. From molecular pathophysiology to clinical trials. Exp Gerontol 2018;113:36–47. Drygalski K, Fereniec E, Koryciński K, Chomentowski A, Kiełczewska A, Odrzygóźdź C, et al. Resveratrol and Alzheimer’s disease. From molecular pathophysiology to clinical trials. Exp Gerontol 2018;113:36–47.
6.
Zurück zum Zitat Shamsher E, Davis BM, Yap TE, Guo L, Cordeiro MF. Neuroprotection in glaucoma: Old concepts, new ideas. Expert Rev Ophthalmol. 2019;14:101–13.CrossRef Shamsher E, Davis BM, Yap TE, Guo L, Cordeiro MF. Neuroprotection in glaucoma: Old concepts, new ideas. Expert Rev Ophthalmol. 2019;14:101–13.CrossRef
7.
Zurück zum Zitat Patel RP, Shamsher E, Hill D, Cordeiro MF. Naturally occurring neuroprotectants in glaucoma. In: Progress in Brain Research. Elsevier B.V.; 2020. p. 119–40. Patel RP, Shamsher E, Hill D, Cordeiro MF. Naturally occurring neuroprotectants in glaucoma. In: Progress in Brain Research. Elsevier B.V.; 2020. p. 119–40.
8.
Zurück zum Zitat Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity. Toxicol Sci. 2004;82:614–9.CrossRefPubMed Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity. Toxicol Sci. 2004;82:614–9.CrossRefPubMed
9.
Zurück zum Zitat Ahmadi Z, Mohammadinejad R, Ashrafizadeh M. Drug delivery systems for resveratrol, a non-flavonoid polyphenol: Emerging evidence in last decades. J Drug Deliv Sci Technol. 2019;51:591–604.CrossRef Ahmadi Z, Mohammadinejad R, Ashrafizadeh M. Drug delivery systems for resveratrol, a non-flavonoid polyphenol: Emerging evidence in last decades. J Drug Deliv Sci Technol. 2019;51:591–604.CrossRef
10.
Zurück zum Zitat Davis BM, Pahlitzsch M, Guo L, Balendra S, Shah P, Ravindran N, et al. Topical curcumin nanocarriers are neuroprotective in eye disease. Sci Rep. 2018;8:11066.CrossRefPubMedPubMedCentral Davis BM, Pahlitzsch M, Guo L, Balendra S, Shah P, Ravindran N, et al. Topical curcumin nanocarriers are neuroprotective in eye disease. Sci Rep. 2018;8:11066.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21:201–30.CrossRefPubMed Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21:201–30.CrossRefPubMed
12.
Zurück zum Zitat Davis BM, Normando EM, Guo L, Turner LA, Nizari S, O’Shea P, et al. Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes. Small. 2014;10:1575–84.CrossRefPubMed Davis BM, Normando EM, Guo L, Turner LA, Nizari S, O’Shea P, et al. Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes. Small. 2014;10:1575–84.CrossRefPubMed
14.
Zurück zum Zitat Khan RS, Dine K, Bauman B, Lorentsen M, Lin L, Brown H, et al. Intranasal delivery of a novel amnion cell secretome prevents neuronal damage and preserves function in a mouse multiple sclerosis model. Sci Rep. 2017;7:41768.CrossRefPubMedPubMedCentral Khan RS, Dine K, Bauman B, Lorentsen M, Lin L, Brown H, et al. Intranasal delivery of a novel amnion cell secretome prevents neuronal damage and preserves function in a mouse multiple sclerosis model. Sci Rep. 2017;7:41768.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Willett K, Khan RS, Dine K, Wessel H, Kirshner ZZ, Sauer JL, et al. Neuroprotection mediated by ST266 requires full complement of proteins secreted by amnion-derived multipotent progenitor cells. PLoS ONE. 2021;16: e0243862.CrossRefPubMedPubMedCentral Willett K, Khan RS, Dine K, Wessel H, Kirshner ZZ, Sauer JL, et al. Neuroprotection mediated by ST266 requires full complement of proteins secreted by amnion-derived multipotent progenitor cells. PLoS ONE. 2021;16: e0243862.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Khan RS, Ross AG, Willett K, Dine K, Banas R, Brown LR, et al. Amnion-derived multipotent progenitor cells suppress experimental optic neuritis and myelitis. Neurother. 2020;181(18):448–59. Khan RS, Ross AG, Willett K, Dine K, Banas R, Brown LR, et al. Amnion-derived multipotent progenitor cells suppress experimental optic neuritis and myelitis. Neurother. 2020;181(18):448–59.
17.
Zurück zum Zitat Guo Y, Luo J, Tan S, Otieno BO, Zhang Z. The applications of vitamin e TPGS in drug delivery. Eur J Pharm Sci. 2013;49:175–86.CrossRefPubMed Guo Y, Luo J, Tan S, Otieno BO, Zhang Z. The applications of vitamin e TPGS in drug delivery. Eur J Pharm Sci. 2013;49:175–86.CrossRefPubMed
18.
Zurück zum Zitat Nassir AM, Shahzad N, Ibrahim IAA, Ahmad I, Md S, Ain MR. Resveratrol-loaded PLGA nanoparticles mediated programmed cell death in prostate cancer cells. Saudi Pharm J. 2018;26:876–85.CrossRefPubMedPubMedCentral Nassir AM, Shahzad N, Ibrahim IAA, Ahmad I, Md S, Ain MR. Resveratrol-loaded PLGA nanoparticles mediated programmed cell death in prostate cancer cells. Saudi Pharm J. 2018;26:876–85.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Wan S, Zhang L, Quan Y, Wei K. Resveratrol-loaded PLGA nanoparticles: Enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy. R Soc Open Sci. 2018;5: 181457.CrossRefPubMedPubMedCentral Wan S, Zhang L, Quan Y, Wei K. Resveratrol-loaded PLGA nanoparticles: Enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy. R Soc Open Sci. 2018;5: 181457.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Wang Y, Pi C, Feng X, Hou Y, Zhao L, Wei Y. The influence of nanoparticle properties on oral bioavailability of drugs. Int J Nanomedicine. 2020;15:6295–310.CrossRefPubMedPubMedCentral Wang Y, Pi C, Feng X, Hou Y, Zhao L, Wei Y. The influence of nanoparticle properties on oral bioavailability of drugs. Int J Nanomedicine. 2020;15:6295–310.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Pandita D, Kumar S, Poonia N, Lather V. Solid lipid nanoparticles enhance oral bioavailability of resveratrol, a natural polyphenol. Food Res Int. 2014;62:1165–74.CrossRef Pandita D, Kumar S, Poonia N, Lather V. Solid lipid nanoparticles enhance oral bioavailability of resveratrol, a natural polyphenol. Food Res Int. 2014;62:1165–74.CrossRef
22.
Zurück zum Zitat Kamath MS, Ahmed SSSJ, Dhanasekaran M, Winkins SS. Polycaprolactone scaffold engineered for sustained release of resveratrol: Therapeutic enhancement in bone tissue engineering. Int J Nanomedicine. 2013;9:183–95.PubMedPubMedCentral Kamath MS, Ahmed SSSJ, Dhanasekaran M, Winkins SS. Polycaprolactone scaffold engineered for sustained release of resveratrol: Therapeutic enhancement in bone tissue engineering. Int J Nanomedicine. 2013;9:183–95.PubMedPubMedCentral
23.
Zurück zum Zitat Vijayakumar MR, Kumari L, Patel KK, Vuddanda PR, Vajanthri KY, Mahto SK, et al. Intravenous administration of: Trans -resveratrol-loaded TPGS-coated solid lipid nanoparticles for prolonged systemic circulation, passive brain targeting and improved in vitro cytotoxicity against C6 glioma cell lines. RSC Adv. 2016;6:50336–48.CrossRef Vijayakumar MR, Kumari L, Patel KK, Vuddanda PR, Vajanthri KY, Mahto SK, et al. Intravenous administration of: Trans -resveratrol-loaded TPGS-coated solid lipid nanoparticles for prolonged systemic circulation, passive brain targeting and improved in vitro cytotoxicity against C6 glioma cell lines. RSC Adv. 2016;6:50336–48.CrossRef
24.
Zurück zum Zitat Vijayakumar MR, Kosuru R, Singh SK, Prasad CB, Narayan G, Muthu MS, et al. Resveratrol loaded PLGA:D-α-tocopheryl polyethylene glycol 1000 succinate blend nanoparticles for brain cancer therapy. RSC Adv. 2016;6:74254–68.CrossRef Vijayakumar MR, Kosuru R, Singh SK, Prasad CB, Narayan G, Muthu MS, et al. Resveratrol loaded PLGA:D-α-tocopheryl polyethylene glycol 1000 succinate blend nanoparticles for brain cancer therapy. RSC Adv. 2016;6:74254–68.CrossRef
25.
Zurück zum Zitat Siu F, Ye S, Lin H, Li S. Galactosylated PLGA nanoparticles for the oral delivery of resveratrol: Enhanced bioavailability and in vitro anti-inflammatory activity. Int J Nanomedicine. 2018;13:4133–44.CrossRefPubMedPubMedCentral Siu F, Ye S, Lin H, Li S. Galactosylated PLGA nanoparticles for the oral delivery of resveratrol: Enhanced bioavailability and in vitro anti-inflammatory activity. Int J Nanomedicine. 2018;13:4133–44.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Khan RS, Dine K, Das Sarma J, Shindler KS. SIRT1 Activating compounds reduce oxidative stress mediated neuronal loss in viral induced CNS demyelinating disease. Acta Neuropathol Commun. 2014;2:3.CrossRefPubMedPubMedCentral Khan RS, Dine K, Das Sarma J, Shindler KS. SIRT1 Activating compounds reduce oxidative stress mediated neuronal loss in viral induced CNS demyelinating disease. Acta Neuropathol Commun. 2014;2:3.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Qi X, Lewin AS, Sun L, Hauswirth WW, Guy J. Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis. Investig Ophthalmol Vis Sci. 2007;48:681–91.CrossRef Qi X, Lewin AS, Sun L, Hauswirth WW, Guy J. Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis. Investig Ophthalmol Vis Sci. 2007;48:681–91.CrossRef
28.
Zurück zum Zitat Guy J, Ellis A, Mames R, Rao NA. Role of hydrogen peroxide in experimental optic neuritis. Ophthalmic Res. 1993;25:253–64.CrossRefPubMed Guy J, Ellis A, Mames R, Rao NA. Role of hydrogen peroxide in experimental optic neuritis. Ophthalmic Res. 1993;25:253–64.CrossRefPubMed
29.
Zurück zum Zitat Shindler KS, Ventura E, Dutt M, Elliott P, Fitzgerald DC, Rostami A. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuro-Ophthalmology. 2010;30:328–39.CrossRef Shindler KS, Ventura E, Dutt M, Elliott P, Fitzgerald DC, Rostami A. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuro-Ophthalmology. 2010;30:328–39.CrossRef
30.
Zurück zum Zitat Xu L, Botchway BOA, Zhang S, Zhou J, Liu X. Inhibition of NF-κB signaling pathway by resveratrol improves spinal cord injury. Front Neurosci. 2018;12:690.CrossRefPubMedPubMedCentral Xu L, Botchway BOA, Zhang S, Zhou J, Liu X. Inhibition of NF-κB signaling pathway by resveratrol improves spinal cord injury. Front Neurosci. 2018;12:690.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Latruffe N, Lançon A, Frazzi R, Aires V, Delmas D, Michaille JJ, et al. Exploring new ways of regulation by resveratrol involving miRNAs, with emphasis on inflammation. Ann N Y Acad Sci. 2015;1348:97–106.CrossRefPubMed Latruffe N, Lançon A, Frazzi R, Aires V, Delmas D, Michaille JJ, et al. Exploring new ways of regulation by resveratrol involving miRNAs, with emphasis on inflammation. Ann N Y Acad Sci. 2015;1348:97–106.CrossRefPubMed
32.
Zurück zum Zitat Ghaiad HR, Nooh MM, El-Sawalhi MM, Shaheen AA. Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: Biochemical and histological study. Mol Neurobiol. 2017;54:3219–29.CrossRefPubMed Ghaiad HR, Nooh MM, El-Sawalhi MM, Shaheen AA. Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: Biochemical and histological study. Mol Neurobiol. 2017;54:3219–29.CrossRefPubMed
33.
Zurück zum Zitat Shindler KS, Ventura E, Rex TS, Elliott P, Rostami A. SIRT1 activation confers neuroprotection in experimental optic neuritis. Investig Opthalmology Vis Sci. 2007;48:3602.CrossRef Shindler KS, Ventura E, Rex TS, Elliott P, Rostami A. SIRT1 activation confers neuroprotection in experimental optic neuritis. Investig Opthalmology Vis Sci. 2007;48:3602.CrossRef
34.
Zurück zum Zitat McDougald DS, Dine KE, Zezulin AU, Bennett J, Shindler KS. SIRT1 and NRF2 gene transfer mediate distinct neuroprotective effects upon retinal ganglion cell survival and function in experimental optic neuritis. Invest Ophthalmol Vis Sci. 2018;59:1212–20.CrossRefPubMedPubMedCentral McDougald DS, Dine KE, Zezulin AU, Bennett J, Shindler KS. SIRT1 and NRF2 gene transfer mediate distinct neuroprotective effects upon retinal ganglion cell survival and function in experimental optic neuritis. Invest Ophthalmol Vis Sci. 2018;59:1212–20.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Ross AG, Chaqour B, McDougald DS, Dine KE, Duong TT, Shindler RE, et al. Selective Upregulation of SIRT1 expression in retinal ganglion cells by AAV-mediated gene delivery increases neuronal cell survival and alleviates axon demyelination associated with optic neuritis. Biomolecules. 2022;12. Ross AG, Chaqour B, McDougald DS, Dine KE, Duong TT, Shindler RE, et al. Selective Upregulation of SIRT1 expression in retinal ganglion cells by AAV-mediated gene delivery increases neuronal cell survival and alleviates axon demyelination associated with optic neuritis. Biomolecules. 2022;12.
Metadaten
Titel
Nanoparticles Enhance Solubility and Neuroprotective Effects of Resveratrol in Demyelinating Disease
verfasst von
Ehtesham Shamsher
Reas S. Khan
Benjamin M. Davis
Kimberly Dine
Vy Luong
Satyanarayana Somavarapu
M. Francesca Cordeiro
Kenneth S. Shindler
Publikationsdatum
09.05.2023
Verlag
Springer International Publishing
Erschienen in
Neurotherapeutics / Ausgabe 4/2023
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-023-01378-0

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Neurologie

Kaliumhaltiges Kochsalz schützt vor Schlaganfallrezidiven

Erhalten Menschen nach einem Schlaganfall statt normalem Kochsalz eine kaliumhaltige Alternative, reduziert dies sowohl das Risiko für erneute ischämische und hämorrhagische Insulte als auch die Gesamtmortalität. Dafür sprechen Ergebnisse einer großen randomisierten Studie.

Der Mann mit der Alzheimermutation, der keine Demenz bekommt

Nur sehr selten werden Menschen mit einer Alzheimermutation von einer familiären Demenz verschont, was meist an protektiven Genvarianten liegt. Ein über 70-jähriger Mann stellt die Forschung jedoch vor ein Rätsel. Vielleicht hat ihm die Arbeit in großer Hitze geholfen.

Auch nach TIA kommt es zu kognitivem Abbau

Trotz raschem und vollständigem Verschwinden der Symptome bergen auch transitorische ischämische Attacken das Risiko langfristigen kognitiven Abbaus, wie eine Studie zeigt. Die Größenordnung gleicht jener nach einem Schlaganfall.

Schlaganfall oder Schlaganfall-Imitator?

Ein breites Spektrum von Erkrankungen kann einen Schlaganfall vortäuschen. Bei der notwendigen schnellen Unterscheidung zwischen solchen „stroke mimics“ und echten Schlaganfällen können einige klinische Faktoren und Symptome unterstützend herangezogen werden. 

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.